Siegfried has inked a deal to acquire Curia Global’s early-phase manufacturing site in Grafton, Wisconsin, in a move that expands the Swiss CDMO’s reach in the U.S. and its ability to offer a wider range of services.

The sale comes a little more than two months after Siegfried’s chief executive was poached by rival Lonza.

Although financial details of the facility purchase from Curia weren’t disclosed, the sale is expected to wrap up by July 1 and is being financed from existing company funds, Siegfried said in a June 12 press release.

The Wisconsin facility specializes in early-phase development and manufacturing services and employs more than 80 workers. Siegfried said it plans to develop the site into a hub for early-phase CDMO services for its global customers, which will include services for projects with highly potent drug ingredients.

“With this acquisition, we enhance our offering with early-stage development services for drug substances and become even more relevant and attractive to our customers,” Reto Suter, Siegfried’s interim CEO and CFO, said in the release. “This transaction will generate attractive opportunities and will further accelerate our growth story.”

Suter is filling in as chief executive after the news broke in early April that 14-year Siegfried veteran Wolfgang Wienand was leaving to take the helm at Swiss compatriot Lonza. Wienand’s role at Lonza is expected to begin this summer.

Lonza experienced several years of leadership fluctuations since Richard Ridinger left the company in early 2019.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.